Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE-MM2 trial.
Paul G Richardson, Thierry Facon, Christopher P Venner, Nizar J Bahlis, Fritz Offner, Darrell White, Lionel Karlin, Lotfi Benboubker, Eric Voog, Sung-Soo Yoon and 11 more
Article in EJHaem, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 27% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
3 citing papers in PubMed, 2 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
21 authors at 17 institutions in 6 countries.
Paul G RichardsonHarvard Medical School Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute Boston Massachusetts USA.ORCID https://orcid.org/0000-0002-7426-8865
Thierry FaconCentre Hospitalier Universitaire (CHU) Lille Service des Maladies du Sang, University of Lille Lille France.
Christopher P VennerCross Cancer Institute University of Alberta Edmonton Alberta Canada.
Hirohiko ShibayamaOsaka University Graduate School of Medicine Suita Osaka Japan.
Xiaoquan ZhangTakeda Development Center Americas, Inc. (TDCA) Lexington Massachusetts USA.
Miguel VillarrealTakeda Development Center Americas, Inc. (TDCA) Lexington Massachusetts USA.
Philip Twumasi-AnkrahTakeda Development Center Americas, Inc. (TDCA) Lexington Massachusetts USA.
Richard LabotkaTakeda Development Center Americas, Inc. (TDCA) Lexington Massachusetts USA.
Robert M RifkinUS Oncology Research - Rocky Mountain Cancer Centers Denver Colorado USA.
Sagar LonialDepartment of Hematology and Medical Oncology Winship Cancer Institute Emory University School of Medicine Atlanta Georgia USA.
Shaji K KumarMayo Clinic Rochester Minnesota USA.
S Vincent RajkumarMayo Clinic Rochester Minnesota USA.
Philippe MoreauCentre Hospitalier Universitaire de Nantes Nantes France.
Takeda (United States) · USMayo Clinic · USBC Cancer Agency · CACentre Hospitalier Universitaire de Nantes · FRCentre Hospitalier Universitaire de Tours · FRClinique Victor Hugo · FRDalhousie University · CAEmory University · USGhent University Hospital · BEHarvard University · USHôpital Lyon Sud · FRJapanese Red Cross Medical Center · JPOsaka Gakuin University · JPRocky Mountain Cancer Centers · USSeoul National University Hospital · KRUniversité de Lille · FRUniversity of Calgary · CA
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Deeper responses are associated with longer survival in multiple myeloma (MM); however, limited data exist on the impact of response kinetics on outcomes. We investigated progression-free survival (PFS) and duration of response (DOR) by response depth and in early (best confirmed response 0-4 months;
Indexed as
depth of responseixazomibmultiple myelomaresponse kinetics
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE-MM2 trial. · full record | OpenQuestion